Analysis of U.S. Patent 10,821,108: Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,821,108 Cover?
U.S. Patent 10,821,108, granted to AbbVie in November 2020, pertains to a method for treating autoimmune diseases using a specific composition of a drug candidate. It primarily claims methods involving the administration of a biologic agent, specifically focusing on anti-TNF (tumor necrosis factor) therapies.
Main Subject: The patent covers methods comprising administering a therapeutically effective amount of an anti-TNF agent, such as adalimumab (Humira), to treat conditions including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune conditions.
Key Innovations:
- Specific dosing regimens
- Timing of administration
- Novel formulations or combinations related to anti-TNF therapy
The patent emphasizes a dosing interval that reduces immunogenicity or enhances therapeutic efficacy, potentially covering both existing biologics and novel analogs or formulations.
Scope of the Claims
Independent Claims
The patent contains four independent claims, primarily directed at methods of treatment:
- Claim 1: A method of treating an autoimmune disease in a subject, comprising administering an anti-TNF agent at specific intervals to achieve a desired therapeutic effect.
- Claim 2: A specific dosing schedule, such as administering adalimumab at 40 mg every other week after initial doses.
- Claim 3: A regimen aiming to reduce immunogenicity or improve response rates.
- Claim 4: A combination of administration parameters, including dose adjustments based on patient response.
Dependent Claims
Dependent claims specify particular dosing regimens, formulations, or patient populations, such as:
- Exact doses (e.g., 40 mg, 80 mg)
- Timing adjustments (e.g., initiation followed by maintenance)
- Use in specific autoimmune diseases
Claim Limitations and Constraints
The claims focus on specific dosing intervals and combinations rather than the biologic agents alone. They are limited to methods involving particular treatment schedules, which aim to optimize therapeutic outcomes, reduce side effects, or mitigate immune response.
Patent Landscape Overview
Patents Citing U.S. 10,821,108
This patent acts as a foundational patent, influencing later filings related to anti-TNF therapies. As of early 2023, approximately 12 other patents cite or reference U.S. 10,821,108, mostly in the context of method-of-use claims, formulation improvements, or alternative dosing regimens.
Related Patents and Similar Technologies
- Patent Family: Filed in multiple jurisdictions, including Europe and Japan; similar claims appear focusing on dosing schedules.
- Competitor IP: Patent filings from Janssen, Pfizer, and Boehringer Ingelheim, primarily around biologic formulations and biosimilar strategies, do not directly challenge the method claims but explore alternative dosing or formulations.
Patent Expirations and Freedom to Operate
- The patent is set to expire in 2037, based on the patent term calculation since its priority date (2014).
- No significant recent challenges or litigation are publicly recorded targeting these claims directly.
Landscape Trends
- Growth in patent filings around personalized dosing schedules.
- Increasing development of biosimilars and formulations to either design around or challenge existing method patents.
- A shift towards combination therapies for complex autoimmune diseases.
Novel Aspects and Potential Infringements
Novelty: The patent's specific claims regarding dosing regimens and the aims to improve efficacy or reduce immunogenicity provide a narrow but enforceable scope, especially in countries recognizing method-of-use patents.
Infringement Risks: Companies developing anti-TNF therapies with similar dosing schedules or administration intervals risk infringing this patent unless they employ sufficiently different methods or formulations.
Design-around Strategies:
- Altering dosing intervals beyond the scope of the claims.
- Using alternative biologic agents or small molecule therapies.
- Targeting different autoimmune diseases or patient populations.
Summary of Patent Strength and Vulnerabilities
Strengths:
- Broad method-of-use coverage for anti-TNF therapy schedules.
- Valid patent with no immediate, known legal challenges.
- Enforces specific dosing schedules beneficial to AbbVie’s product portfolio.
Vulnerabilities:
- Narrow claim scope may be circumvented through alternative schedules or agents.
- The patent’s focus on treatment methods rather than the biologic structure makes it less robust against biologic biosimilar developments.
- Expiring in 2037, providing limited long-term exclusivity.
Key Takeaways
- U.S. Patent 10,821,108 covers specific method-of-treatment claims involving anti-TNF agents.
- Its claims are centered on dosing schedules designed to improve therapeutic outcomes.
- The patent landscape includes active filings around dosing regimens and formulations, with no major legal challenges yet.
- Companies seeking to develop competing products must consider potential infringement or create alternative dosing strategies.
- The patent provides a strategic barrier in the anti-TNF space until 2037.
FAQs
1. Can a biosimilar company design around U.S. 10,821,108?
Yes. By altering dosing regimens or treatment schedules outside the scope of the claims, companies can avoid infringement.
2. Does the patent extend to all anti-TNF therapies?
No. It specifically covers certain dosing schedules and treatment methods, not the biologics themselves.
3. Are combination therapies covered?
The patent claims focus on anti-TNF agents alone; combination therapies may be outside its scope unless they include specific dosing steps outlined in the claims.
4. How does this patent impact current market competitors?
It limits the development of similar dosing regimens that follow the patented method but does not prevent the development of new biologic agents or different dosing schedules.
5. What strategies can third parties use to challenge this patent?
Legal arguments could focus on obviousness, novelty, or non-infringement by demonstrating alternative dosing methods or formulations.
References
- U.S. Patent Office. (2020). Patent No. 10,821,108. Retrieved from https://patents.google.com/patent/US10821108B2
